Treatment With Efmoroctocog Alfa (Elocta®) in Hemophilia: A Case Series

Ezio Zanon, Alberto Tosetto, Paolo Radossi, Samantha Pasca, Elisa Bonetti, Simone Cesaro, Anna Chiara Giuffrida

DOI: https://doi.org/10.7175/cmi.v14i1.1484

Abstract

Hemophilia A is a rare X-linked disease that occurs as a result of a defect in the FVIII-encoding gene. The reduction or absence of plasma FVIII compromises the coagulation cascade, resulting in frequent bleeds, especially in joints or soft tissues. Currently, replacement therapy with coagulation factor concentrates is the gold standard for the treatment of FVIII deficiency.

Herein, we report a case series of five hemophilia A patients treated with an extended half-life recombinant human coagulation factor, FVIII-Fc fusion protein (efmoroctocog alfa). The prophylactic regimen for each patient was individualized based on their pharmacokinetic profile.

Compared to previous prophylactic treatments, most patients received a reduced weekly dose of concentrate, all underwent a reduced frequency of administration, the annualized bleeding rates (ABR) and hemophilia joint health scores (HJHS) were stable or improved. The half-life of efmoroctocog alfa and the 72-hour trough levels were higher than those observed in the A-LONG Phase III trial.

In conclusion, all patients reported clinical improvements and general subjective wellbeing in the absence of significant safety concerns after switching to efmoroctocog alfa.

 

Keywords

Hemophilia A; FVIIIFc; Efmoroctocog alfa; Bleeding; Extended Half-Life; Recombinant Factor VIII

Full Text

HTML PDF

References

  • Orphanet. Emofilia A grave. Available at https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=IT&data_id=17872&Disease_Disease_Search_diseaseGroup=emofilia&Disease_Disease_Search_diseaseType=Pat&Malattia(e)/%20gruppo%20di%20malattie=Emofilia-A-grave&title=Emofilia%20A%20grave&search=Disease_Search_Simple (last accessed October 2020)
  • World Federation of Hemophilia. Report on the Annual Global Survey 2017. October 2018. Available at http://www1.wfh.org/publications/files/pdf-1714.pdf (last accessed October 2020)
  • Rocino A, Coppola A, Franchini M, et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 2014; 12: 575-98; https://doi.org/10.2450/2014.0223-14
  • Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia: The Official Journal of the World Federation of Hemophilia 2020; 26 Suppl 6: 1-158; https://doi.org/10.1111/hae.14046
  • Margaglione M, Castaman G, Morfini M, et al. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica 2008; 93: 722-8; https://doi.org/10.3324/haematol.12427
  • Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-e47; https://doi.org/10.1111/j.1365-2516.2012.02909.x
  • McCue J, Kshirsagar R, Selvitelli K, et al. Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein. Biologicals 2015; 43: 213-9; https://doi.org/10.1016/j.biologicals.2015.05.012
  • Lippi G, Favaloro EJ. Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A. Advances in Clinical Chemistry. Vol. 88. Elsevier; 2019:151-67.
  • Dumont JA, Liu T, Low SC, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood 2012; 119: 3024-30; https://doi.org/10.1182/blood-2011-08-367813
  • Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031-7; https://doi.org/10.1182/blood-2011-09-382846
  • Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25; https://doi.org/10.1182/blood-2013-10-529974
  • Peters RT, Toby G, Lu Q, et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost 2013; 11: 132-41; https://doi.org/10.1111/jth.12076
  • Mancuso ME, Mannucci PM. Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias. Drug Des Devel Ther 2014; 8: 365-71; https://doi.org/10.2147/DDDT.S47312
  • Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015; 13: 967-77; https://doi.org/10.1111/jth.12911
  • Nolan B, Mahlangu J, Pabinger I, et al. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia 2020; 26: 494-502; https://doi.org/10.1111/hae.13953
  • European Medicines Agency. Elocta. Available at https://www.ema.europa.eu/en/medicines/human/EPAR/elocta. Published September 17, 2018 (last accessed October, 2020)
  • Benson G, Auerswald G, Dolan G, et al. Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus 2018; 16: 535-44; https://doi.org/10.2450/2017.0150-17
  • CDC. CHAMP | Hemophilia | CDC. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/ncbddd/hemophilia/champs.html. Published February 27, 2017 (last accessed October, 2020)
  • Franchini M, Lippi G. Recombinant Factor VIII Concentrates. Semin Thromb Hemost 2010; 36: 493-7; https://doi.org/10.1055/s-0030-1255443

Statistics

Abstract: 71 views
HTML: 38 views
PDF: 56 views

Refbacks

  • There are currently no refbacks.




© SEEd srl